CancerDrs Find care

Testicular Cancer clinical trials

29 actively recruiting testicular cancer trials in the United States. Highly curable germ cell tumors. Trials focus on reducing toxicity of curative therapy and treating relapsed/refractory disease.

Data from ClinicalTrials.gov · last refreshed · Testicular Cancer stats on SEER

5
Phase 1
5
Phase 2
3
Phase 3
16
Other

Testicular Cancer by the numbers (U.S.)

9,720
Estimated new cases (2025)
600
Estimated deaths (2025)
94.9%
5-year relative survival
33
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse testicular cancer trials by state

California 14 Pennsylvania 11 New York 10 North Carolina 10 Minnesota 9 New Jersey 9 Ohio 9 Colorado 8 Florida 8 Illinois 8 Massachusetts 8 Tennessee 8 Arizona 7 Maryland 7 Texas 7 Wisconsin 7 Alabama 6 Arkansas 6 Georgia 6 Indiana 6 Iowa 6 Michigan 6 Missouri 6 Nebraska 6 North Dakota 6 Oklahoma 6 Kansas 5 Louisiana 5 Oregon 5 South Carolina 5 Virginia 5 Washington 5 Alaska 4 Connecticut 4 Delaware 4 Idaho 4 Kentucky 4 Mississippi 4 Montana 4 Nevada 4 Rhode Island 4 District of Columbia 3 Maine 3 New Mexico 3 Utah 3 Vermont 3 West Virginia 3 Hawaii 2 New Hampshire 2 South Dakota 2 Wyoming 2

Top trials by phase + site coverage

Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • USA Health Strada Patient Care Center — Mobile, Alabama
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska

+ 564 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • USA Health Strada Patient Care Center — Mobile, Alabama
  • Providence Alaska Medical Center — Anchorage, Alaska

+ 200 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.

This randomization study is to compare both intrathecal morphine and intravenous methadone, which are both standard of care, for pain management in patients undergoing retroperitoneal lymph node dissections for primary testicular cancer. I…

Sponsor: Indiana University
NCT ID: NCT06593665
Locations:
  • Indiana Univeristy — Indianapolis, Indiana
  • Indiana University Hospital — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Anchorage Radiation Therapy Center — Anchorage, Alaska

+ 576 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicy…

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06866964
Locations:
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Charlotte, North Carolina
  • Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
  • Aurora St. Luke's Medical Center MOB — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (adv…

Sponsor: Mayo Clinic
NCT ID: NCT05969860
Locations:
  • Mayo Clinic in Florida — Jacksonville, Florida
  • Altru Cancer Center — Grand Forks, North Dakota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 pat…

Sponsor: University of Arizona
NCT ID: NCT06814496
Locations:
  • Arizona Cancer Center at UMC North/University Medical Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Background: Many cancers of the testicles and urinary tract are rare diseases; these are diseases that affect less than 200,000 people in the United States. It can be hard to study treatments for these diseases. One combination of drugs-en…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06041503
Locations:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tu…

Sponsor: Xencor, Inc.
NCT ID: NCT06276491
Locations:
  • City of Hope — Duarte, California
  • Stanford — Palo Alto, California
  • University of California — San Francisco, California

+ 13 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ov…

Sponsor: Context Therapeutics Inc.
NCT ID: NCT06515613
Locations:
  • University of Arkansas Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas
  • Precision NextGen Oncology & Research Center — Beverly Hills, California
  • SCRI at Denver Health — Denver, Colorado

+ 10 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

This phase I trial evaluates whether adding Pedmark to standard of care cisplatin-based chemotherapy reduces drug-induced ear damage (ototoxicity) in men with stage II-III testicular germ cell tumors that have spread from where they first …

Sponsor: City of Hope Medical Center
NCT ID: NCT07218913
Locations:
  • City of Hope Medical Center — Duarte, California
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Brodalumab in the Treatment of Immune-Related Adverse Events

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who p…

Sponsor: Brian Henick, MD
NCT ID: NCT06673329
Locations:
  • Columbia University Irving Medical Center — New York, New York
View on ClinicalTrials.gov →

Showing 12 of 29 trials. See all on ClinicalTrials.gov

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20